AdAlta Ltd. (AU:1AD)
ASX:1AD
Top Page
AdAlta Ltd.
(Sydney:1AD)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:10/19/25
AdAlta Ltd. receives an overall stock score of 44, driven primarily by poor financial performance with significant losses, negative equity, and cash burn, posing high sustainability risks in the Biotechnology sector. Valuation concerns due to negative earnings further weigh on the score, while limited technical data adds uncertainty. These critical financial weaknesses are the dominant factors in the low rating.
Positive Factors
Innovative Technology Platform
AdAlta's proprietary i-body platform technology offers a unique approach to developing biologics, potentially providing a competitive edge in the biotechnology sector by addressing unmet medical needs in oncology and other areas.
Negative Factors
Declining Revenue
A significant decline in revenue growth, as indicated by a -30.42% rate, poses a challenge to AdAlta's financial stability and limits its ability to invest in future growth opportunities, impacting long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Technology Platform
AdAlta's proprietary i-body platform technology offers a unique approach to developing biologics, potentially providing a competitive edge in the biotechnology sector by addressing unmet medical needs in oncology and other areas.
Read all positive factors
AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$10.20M
Dividend YieldN/A
Average Volume (3M)574.71K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth31.87%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,549,669,000
10 Day Avg. Volume957,709
30 Day Avg. Volume574,705
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-4.36
Price to Sales (P/S)3.86
P/FCF Ratio-0.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AdAlta Ltd. Business Overview & Revenue Model
Company Description
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmona...
How the Company Makes Money
AdAlta generates revenue primarily through a combination of research grants, collaborative agreements, and licensing deals. The company partners with pharmaceutical and biotechnology firms to co-develop its drug candidates, leveraging its i-body t...
AdAlta Ltd. Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 301.92K | 677.01K | 1.74M | 3.47M | 2.75M | 848.19K |
| Gross Profit | 181.81K | 457.50K | 1.51M | 3.44M | 2.49M | 848.19K |
| EBITDA | -4.47M | -4.45M | -5.26M | -7.58M | -7.31M | -8.36M |
| Net Income | -4.36M | -4.50M | -5.38M | -4.85M | -6.06M | -5.63M |
Balance Sheet | ||||||
| Total Assets | 1.85M | 2.14M | 5.57M | 7.73M | 10.65M | 9.05M |
| Cash, Cash Equivalents and Short-Term Investments | 1.58M | 1.31M | 3.13M | 4.79M | 8.66M | 5.79M |
| Total Debt | 0.00 | 1.77M | 2.70M | 4.01M | 4.00M | 1.69M |
| Total Liabilities | 2.07M | 2.74M | 3.54M | 5.82M | 5.27M | 2.66M |
| Stockholders Equity | -218.66K | -598.24K | 2.03M | 1.91M | 5.38M | 6.39M |
Cash Flow | ||||||
| Free Cash Flow | -2.44M | -2.94M | -5.32M | -5.13M | -4.11M | -4.78M |
| Operating Cash Flow | -2.44M | -2.94M | -5.26M | -5.13M | -4.09M | -4.78M |
| Investing Cash Flow | 109.61K | 109.61K | -62.40K | -2.13K | -25.23K | -2.12K |
| Financing Cash Flow | 2.29M | 999.06K | 3.67M | 1.27M | 7.02M | 7.19M |
AdAlta Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$13.12M | -1.00 | -218.76% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$8.02M | -3.28 | 265.12% | ― | ― | 24.09% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
44 Neutral | AU$9.76M | -1.25 | -140.35% | ― | ― | ― | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% |
* Healthcare Sector Average
AU:1AD
AdAlta Ltd.
―
―
―
AU:VBS
Vectus Biosystems Limited
0.15
0.07
97.37%
AU:CMB
Regeneus Ltd.
0.48
0.16
50.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
AU:BGT
Bio-Gene Technology Ltd.
0.03
>-0.01
-3.03%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AdAlta Ltd. Corporate Events
AdAlta’s AdCella Strikes Global Deal for Armoured CAR‑T Cancer Therapy BZDS1901
Jan 1, 2026
AdAlta’s cell therapy subsidiary AdCella has signed a Development and Collaboration Agreement with Shanghai Cell Therapy Group to co-develop BZDS1901, a first-in-class, PD1‑armoured mesothelin-targeting CAR‑T therapy, for all mar...
AdAlta Ltd Director Adjusts Securities Holdings
Dec 4, 2025
AdAlta Ltd has announced a change in the interests of its director, Tim Oldham, involving the disposal of 1,200,000 unlisted options and 1,396,999 performance rights, while acquiring 1,396,999 ordinary shares. This change reflects a strategic adju...
AdAlta Ltd. Announces Cessation of Securities Due to Expiry
Dec 4, 2025
AdAlta Ltd. announced the cessation of 6,655,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 29, 2025. This development may impact the company’s capital structure and ...
AdAlta Completes Major Share and Options Issuance
Dec 4, 2025
AdAlta Limited announced the completion of issuing 401,676,129 ordinary shares and 277,666,667 options, as well as 1,396,999 ordinary shares from employee performance rights. This issuance was conducted without disclosure to investors under specif...
AdAlta Ltd. Announces Quotation of New Securities on ASX
Dec 3, 2025
AdAlta Ltd. announced the quotation of 388,666,666 fully paid ordinary securities and 194,333,333 options expiring in June 2028 on the ASX. This move is part of previously announced transactions and is expected to enhance the company’s finan...
AdAlta Ltd. Announces Quotation of New Securities on ASX
Dec 3, 2025
AdAlta Ltd. announced the application for quotation of 1,396,999 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and support its ongoing...
AdAlta Ltd. Announces Quotation of New Securities on ASX
Dec 3, 2025
AdAlta Ltd. has announced the quotation of new securities on the Australian Securities Exchange (ASX), including 13,009,463 ordinary fully paid shares and 83,333,334 options expiring in June 2028. This move is part of previously announced transact...
AdAlta Ltd. Announces Cessation of Securities
Nov 28, 2025
AdAlta Ltd. announced the cessation of 4,929,060 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 26, 2025. This cessation of securities may impact the company’s capital st...
AdAlta Limited Reports Strong Support at Annual General Meeting
Nov 26, 2025
AdAlta Limited announced that all resolutions at its Annual General Meeting were passed with over 98% support. The company is strategically positioned to dominate the high-growth cellular immunotherapy market, particularly in the treatment of soli...
AdAlta Limited Unveils Strategic Focus at AGM
Nov 25, 2025
AdAlta Limited announced the release of the Chair remarks and CEO presentation at their Annual General Meeting, highlighting their strategic focus on integrating Asian T cell therapy innovations with Western market access. The company aims to domi...
AdAlta Limited Announces Change of Business Address
Nov 13, 2025
AdAlta Limited announced a change in its registered office and principal place of business to a new address in Hawthorn East, Victoria. This move aligns with the company’s strategic focus on advancing its position in the high-growth cellular...
AdAlta Ltd. Cancels Proposed Share Consolidation
Nov 7, 2025
AdAlta Ltd. announced the cancellation of a previous proposal for a 10-for-1 share consolidation, which was initially set to be discussed at the upcoming Annual General Meeting on November 26, 2025. This decision to withdraw the resolution may imp...
AdAlta Withdraws Share Consolidation Proposal from AGM Agenda
Nov 6, 2025
AdAlta Limited has announced the withdrawal of Resolution 6, which proposed a 10 for 1 share consolidation, from its 2025 Annual General Meeting agenda following guidance from corporate advisors. This decision does not affect the validity of proxy...
AdAlta Ltd. Announces Security Consolidation
Oct 29, 2025
AdAlta Ltd. has announced a security consolidation, affecting several of its securities, including ordinary shares and performance rights. This reorganization is set to commence trading on a deferred settlement basis from December 9, 2025, with th...
AdAlta Ltd Announces Director’s Share Acquisition
Oct 29, 2025
AdAlta Ltd has announced a change in the director’s interest, specifically regarding Tim Oldham. The notice details the acquisition of 2,500,000 ordinary shares by Tim Oldham, valued at $8,750. This change reflects an increase in Oldham̵...
AdAlta Limited Completes Share Issuance to Strengthen Financial Position
Oct 28, 2025
AdAlta Limited has completed the issuance of 201,666,666 fully paid ordinary shares at a price of $0.0018 per share. This issuance is part of the company’s funding arrangements with Meurs Group, aimed at addressing outstanding subscription a...
AdAlta Ltd. Announces Quotation of New Securities on ASX
Oct 28, 2025
AdAlta Ltd. has announced the quotation of 201,666,666 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 28, 2025. This move is part of previously announced transactions and is expected to enhance the company...
AdAlta Completes Final Share Issuance Under Meurs Investment Agreement
Oct 28, 2025
AdAlta Limited announced the final issuance of shares under its Investment Agreement with the Meurs Group, a longstanding shareholder. This agreement, initiated in April 2024, provided crucial liquidity and strategic flexibility for AdAlta as it d...
AdAlta Advances ‘East to West’ Strategy with Key Licensing and Financial Milestones
Oct 28, 2025
AdAlta Limited has made significant progress in its ‘East to West’ cellular immunotherapy strategy, with advanced licensing negotiations for its first CAR-T product and plans for a multi-asset collaboration on a second product. The com...
AdAlta Completes Cash Settlement with NLSC, Advances CAR-T Strategy
Oct 24, 2025
AdAlta Limited has completed a cash repayment of $405,132 to New Life Sciences Capital (NLSC), settling the remaining balance of their investment agreement without issuing additional shares. This strategic move, facilitated by NLSC’s initial...
AdAlta Limited Announces Hybrid 2025 AGM and Encourages Electronic Engagement
Oct 24, 2025
AdAlta Limited has announced its 2025 Annual General Meeting (AGM) will be held as a hybrid event, allowing shareholders to participate both in-person and virtually. The company emphasizes the importance of shareholder voting and encourages electr...
AdAlta Ltd. Announces Proposed Securities Issue to Bolster Capital
Oct 20, 2025
AdAlta Ltd. announced a proposed issue of securities, comprising 183,333,333 options expiring on June 3, 2028, and 366,666,667 fully paid ordinary shares, with a proposed issue date of November 26, 2025. This move is likely to impact the company&#...
AdAlta Limited Completes Significant Share Issuance to Investors
Oct 20, 2025
AdAlta Limited has successfully completed the issuance of 153,657,204 fully paid ordinary shares to sophisticated investors through a private placement. This move, announced earlier in October 2025, is part of the company’s strategic efforts...
AdAlta Ltd. Announces Quotation of New Securities on ASX
Oct 20, 2025
AdAlta Ltd. announced the quotation of 153,657,204 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 20, 2025. This move is part of previously announced transactions and is expected to enhance the companyR...
AdAlta Limited Announces Proposed Securities Issue
Oct 12, 2025
AdAlta Limited has announced a proposed issue of 153,657,204 ordinary fully paid securities, scheduled for issuance on October 17, 2025. This move is part of a placement or other type of issue, which could have implications for the company’s...
AdAlta Ltd. Announces Proposed Securities Issue to Boost R&D
Oct 12, 2025
AdAlta Ltd. has announced a proposed issue of securities, involving the issuance of 83,333,334 options expiring in 2028 and 13,009,463 fully paid ordinary shares. This strategic move is aimed at raising capital to support the company’s ongoi...
AdAlta Secures A$0.5 Million Investment to Boost Immunotherapy Strategy
Oct 12, 2025
AdAlta Limited has secured a non-brokered private placement of up to A$0.5 million from a sophisticated Hong Kong investor, enhancing its capacity to pursue its ‘East to West’ cellular immunotherapy strategy. This investment, priced at...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.